Are 10-year booster doses of yellow fever vaccine necessary? Peter Teitelbaum, MD Committee to Advise on Tropical Medicine and Travel (CATMAT)
|
|
- Valentine Grant
- 6 years ago
- Views:
Transcription
1 Are 10-year booster doses of yellow fever vaccine necessary? Peter Teitelbaum, MD Committee to Advise on Tropical Medicine and Travel (CATMAT)
2 Disclosure of Potential for Conflict of Interest Peter Teitelbaum, MD CATMAT Yellow Fever Booster Update FINANCIAL DISCLOSURE Grants/Research Support: None Speakers Bureau/Honoraria: None Consulting Fees: None Other: None
3 What WHO concluded In April 2013, the World Health Organization Strategic Advisory Group of Experts on Immunization concluded that a single primary dose of yellow fever vaccine is sufficient to confer sustained immunity and lifelong protection against yellow fever disease, and that a booster dose is not needed.
4 What ACIP/CDC concluded - I US Advisory Committee on Immunization Practices and CDC 2015: A single dose of YF vaccine provides long-lasting protection and is adequate for most travelers.
5 Why did the question arise?
6 Long-term protection did WHO and CDC come to their conclusions?
7 GRADE Grading of Recommendations Assessment, Development and Evaluation
8
9 Paper 1-98% protection at 20 years Paper 2 76% protection at 40 years Paper 3 80% protection at 35 years Paper 4 -. Conclusion: good protection in long-term (Not real results)
10 GRADE Quality Ranking 1 = HIGH 2 = MODERATE 3 = LOW 4 = VERY LOW For each study and then come up with an overall score
11 GRADE Quality Ranking HIGH MODERATE LOW VERY LOW Why does it matter?
12 GRADE Quality Ranking HIGH MODERATE LOW VERY LOW How do we judge that?
13 GRADE Quality Ranking THE TYPE OF STUDY MATTERS MOST Randomized control trials (RCTs) Observational studies Clinical experience, expert opinion
14 GRADE Quality Ranking 1 = HIGH = Randomized control trials (RCTs) or overwhelming evidence from observational studies 2 = MODERATE = RCTs with important limitations, or exceptionally strong evidence from observational studies 3 = LOW = Observational studies, or RCTs with notable limitations 4 = VERY LOW = Clinical experience and observations, observational studies with important limitations, or RCTs with several major limitations
15 GRADE Quality Ranking Overall quality ranking across all papers: LOW
16 Paper 1-98% protection at 20 years Paper 2 76% protection at 40 years Paper 3 80% protection at 35 years Paper 4 -. But low quality evidence (Not real results)
17 GRADE Conclusion The data indicates that the vaccine is protective in the long-term. The quality of the data is low. (Not a real conclusion. For illustration.)
18
19 WHO, CDC, GRADE
20 What did the data show? Let s first look at how they judged the quality of that data before showing it.
21 DATA QUALITY The data we retrieved provides level 2 evidence Moderate. The data we retrieved provides level 4 evidence Very low.
22 How GRADE Rates Studies By evidence type: 1 = Randomized control trials (RCTs) or overwhelming evidence from observational studies 2 = RCTs with important limitations, or exceptionally strong evidence from observational studies 3 = Observational studies, or RCTs with notable limitations 4 = Clinical experience and observations, observational studies with important limitations, or RCTs with several major limitations
23 Randomized Controlled Trials
24 Field study
25 How GRADE Rates Studies Evidence type: 1 = Randomized control trials (RCTs) Overwhelming evidence from observational studies 2 = RCTs with important limitations, Exceptionally strong evidence from observational studies 3 = Observational studies or RCTs with notable limitations 4 = Clinical experience and observations, observational studies with important limitations or RCTs with several major limitations
26 Observational Studies Preferred observational study types Case Control Studies: none Cohort studies: yes, but not strong
27 How GRADE Rates Studies Evidence type: 1 = Randomized control trials (RCTs) or overwhelming evidence from observational studies 2 = RCTs with important limitations, or exceptionally strong evidence from observational studies 3 = Observational studies RCTs with notable limitations 4 = Clinical experience and observations, observational studies with important limitations or RCTs with several major limitations
28 Observational Studies - Immunized people appear to be spared in outbreaks - Epidemics appear to be stopped by mass immunization - Very few cases in the literature of disease in immunized people despite ½ billion doses administered - Serologic studies
29 Observational Studies Immunized people appear to be spared in outbreaks During these outbreaks, yellow fever disease only occurred in unvaccinated individuals and persons who received yellow fever vaccine several decades previously were protected from developing yellow fever disease (Tomori, personal communication).
30 Observational Studies Epidemics appear to be stopped by mass immunization
31 Observational Studies Very few cases in the literature of disease in immunized people despite ½ billion doses administered CDC: Very low quality evidence (level 4) (incomplete case capture)
32 Observational Studies Serologic studies CDC: Very low quality evidence (level 4) WHO: Moderate quality evidence (level 2)
33 Observational Studies What are serologic studies? Seropositivity vs seroprotection
34 PRNT plaque reduction neutralization test
35 PRNT serology - CDC FDA said, and ACIP/CDC agreed: Measuring antibody using PRNT can indicate the presence of yellow fever neutralizing antibody but what titre is protective has never been adequately demonstrated using this test.
36 PRNT serology - WHO [There is] overall agreement in the assumption that titer>1:10 in plaque reduction neutralization test is associated with protective immunity the working group did note issues and concerns with the lack of a clear correlate of protection in the immune response to yellow fever vaccination. seroprotective levels of neutralizing antibodies, using a PRNT, have not been determined
37 Surrogate evidence She s not my real mother.
38 Problem: Did they really measure only yellow fever antibody in all those studies?
39 Problem: Boosters already?
40 Observational Studies Serologic studies Very low quality evidence (level 4) And the overall level of evidence is level 4
41 Sample size Time since last YF immunization R years 76% strongly positive an mouse study years 100% seropositive mou years 96% seropositive mous years 100% seroprotected;, Ma one dose years 93% seroprotected
42 A too-low threshold was app these people seroprotected years 97% navy/air force seroposit personnel seropositive years 74.5% seroprotected years 13 of 19 of people (68.4%) w years; median 14 yrs 95.2% seroprotected; 9 of 10 >25 years years 84% (26/31) of subjects who 20 years previously were se Comment: This appears to be
43 There is a limited amount of data showing protection in the longer term from one dose of yellow fever vaccine The data provides Level 4 (Very Low) evidence for long term protection. My interpretation: The data shows that the vaccine protects in the long term, and that data is not trustworthy.
44 How did WHO & CDC conclude that the vaccine protects for life?
45 And one more thing. Gambia did mass-immunization, 95% of population in 6 months, in Included in childhood immunization schedule to this day, 80% of population Unique geography has Gambia surrounded by Senegal Gambia has reported 1 case of yellow fever involving an unimmunized tourist
46 An epidemic of yellow fever (YF) occurred in the Gambia between May 1978 and January Retrospective case-finding methods and active surveillance led to the identification of 271 clinically suspected cases. A confirmatory or presumptive laboratory diagnosis was established in 94 cases. In nine survey villages in this area (total population 1,531) the attack rate was %, with a mortality rate of 0.8%, and a case fatality rate of 19.4%. If these villages are representative of the total affected region, there may have been as many as 8,400 cases and 1,600 deaths during the outbreak. Am J Trop Med Hyg Sep;29(5): Yellow fever in the Gambia, : epidemiologic aspects with observations on the occurrence of orungo virus infections.
47
48 GAMBIA Incomplete case capture
49 CATMAT s Recommendations What would you conclude about long-term effectiveness? Would you recommend boosters?
50 What will CATMAT recommend? Continued boosters? No boosters except for special groups?
51 Additional considerations The rarity of yellow fever in Canadians. There have been no labconfirmed cases from nature to-date since testing began in this country in 1974 The known adverse events of the vaccine including the very rare risk of yellow fever vaccine-associated neurologic disease in previously immunized individuals The existence of weak evidence of long-term protection from a single dose as presented above. There is no evidence to the contrary. We would name several exceptions which remove the vulnerable population from this new recommendation We would monitor
52 Immunosuppressed travellers The CATMAT secretariat did a literature review looking for longterm data on YF vaccine protection in immunosuppressed persons: No data found
53
54 What ACIP/CDC concluded - II Additional doses of yellow fever vaccine are recommended for certain travelers: Women who were pregnant Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated Persons who were infected with human immunodeficiency virus when they received their last dose of yellow fever vaccine should receive a dose every 10 years if they continue to be at risk for yellow fever virus infection
55 What ACIP/CDC concluded - III A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 years previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel. This would include travelers who plan to spend a prolonged period in endemic areas or those traveling to highly endemic areas such as rural West Africa during peak transmission season or an area with an ongoing outbreak
56 What ACIP/CDC concluded - IV Laboratory workers who routinely handle wild-type yellow fever virus should have yellow fever virus specific neutralizing antibody titers measured at least every 10 years to determine if they should receive additional doses of the vaccine. For laboratory workers who are unable to have neutralizing antibody titers measured, yellow fever vaccine should be given every 10 years as long as they remain at risk.
Committee to Advise on Tropical Medicine and Travel - CATMAT. Yellow Fever Update 2018 Manitoba Travel Health Conference Yen-Giang Bui, MD, DTMH
Committee to Advise on Tropical Medicine and Travel - CATMAT Yellow Fever Update 2018 Manitoba Travel Health Conference Yen-Giang Bui, MD, DTMH Conflict of interest None 2 Objectives Review CATMAT recommendations
More informationTravel. Program Management. Schedule
Program Management 69_4 YF (yellow fever) vaccine should be offered to all travellers to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated.
More informationCanada s Malaria Recommendations CATMAT
Canada s Malaria Recommendations CATMAT Disclosure of Potential Conflict of Interest Peter Teitelbaum, MD CATMAT Malaria Recommendations FINANCIAL DISCLOSURE Grants/Research Support: None Speakers Bureau/Honoraria:
More informationYellow Fever Vaccination: Doing Away with the Ten Yearly Booster
Yellow Fever Vaccination: Doing Away with the Ten Yearly Booster Philippe Duclos, WHO CISTM14 Québec, 26 May 2015 I have no interest to report Philippe Duclos Outline Background on yellow fever (YF) and
More informationYellow Fever = Bad Disease
Yellow Fever = Bad Disease Dr. David O Freedman Unvaccinated engineer after Amazon trip. Hepatic encephalopathy, ARDS, coma, DIC with spontaneous bleeding. Gross hematuria, 3+ proteinuria, BUN 81, Creatinine
More informationCRED Technical Brief: Outbreaks in Fragile States. Yellow Fever in Darfur September December 2012
1th December 212 CRED Technical Brief: Outbreaks in Fragile States. Yellow Fever in Darfur September December 212 This technical brief consists of 2 sections: 1. An Overview of Yellow Fever (p 1-3) 2.
More informationBelow you will find information about diseases, the risk of contagion, and preventive vaccinations.
Vaccinations Below you will find information about diseases, the risk of contagion, and preventive vaccinations. DTP - Diphtheria Tetanus Polio Yellow fever Hepatitis A Typhoid fever Cerebrospinal meningitis
More informationSummary of Key Points WHO Position Paper on Vaccines against Hepatitis E Virus(HEV) May 2015
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis E Virus(HEV) May 2015 1 Background l Hepatitis E Virus (HEV): leading cause of acute viral hepatitis in developing countries. l Genotypes
More informationHepatitis E FAQs for Health Professionals
Hepatitis E FAQs for Health Professionals Index of Questions ± Overview and Statistics What is Hepatitis E? How common is Hepatitis E in the United States? Where is Hepatitis E most common? Are there different
More informationWHO Technical Consultation on the severity of disease caused by the new influenza A (H1N1) virus infections
WHO Technical Consultation on the severity of disease caused by the new influenza A (H1N1) virus infections Original short summary posted 6 May 2009. Revised full report posted May 9 2009. On 5 May 2009
More informationAdverse Event GACVS. Global Advisory Committee on Vaccine Safety, 910 June 2005
Adverse Event The Committee considered the decision taken by the Government of Japan on 30 May 2005 to suspend routine vaccination with the mouse brainderived Japanese encephalitis (JE) vaccine currently
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationStudy population The study population comprised the general population of Senegal inhabitants aged 1 to 30 years.
Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis Parent du Chatelet I, Gessner B
More informationFact sheet. Yellow fever
Fact sheet Key facts is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow in the name refers to the jaundice that affects some patients. Up to 50% of severely affected
More informationACIP Update, 2014: Summary of February, 2014 Meeting
ACIP Update, 2014: Summary of February, 2014 Meeting Raymond A. Strikas, MD, MPH Immunization Services Division National Center for Immunization and Respiratory Diseases Centers for Disease Control and
More informationYellow fever. Key facts
From: http://www.who.int/en/news-room/fact-sheets/detail/yellow-fever WHO/E. Soteras Jalil Yellow fever 14 March 2018 Key facts Yellow fever is an acute viral haemorrhagic disease transmitted by infected
More informationEpidemiology Update Hepatitis A
December 2011 Epidemiology Update Hepatitis A Hepatitis A Key Points Between 2000 and 2010, 209 cases of hepatitis A were reported in Hennepin County residents. This represents 30% of the cases reported
More informationImmunization of Adults in High Risk Populations. Carol A. Kurbis MD, CCFP, FRCPC WRHA Medical Officer of Health
Immunization of Adults in High Risk Populations Carol A. Kurbis MD, CCFP, FRCPC WRHA Medical Officer of Health OBJECTIVES To review recommendations for immunization in adult populations, with a focus on
More informationRAM U S. D E P A R T M E N T O F H E A L T H. E D U C A T IO N. AND W E LF A R E. J u l y 1970
v u L.u n r. i. v, J u l y 1970 n u n w j y q 6/70 S2.2 J D MILLAR, MO, ACTING 01 RECTOR STATE AND COMMUNITY SERVICES D IV ISIO N BLOG B, ROOM 207 RAM I. C U R R E N T S M A L L P O X M O R B I D I T Y
More informationPublic Health Image Library. CDC/ Cynthia Goldsmith. Image #
Zika Virus Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar,
More informationYellow Fever 29/03/16. Overview. History Transmission Yellow fever disease New internaaonal recommendaaons Late breaking news
Overview Yellow Fever Yellow fever should be dealt with as an enemy which imperils life and cripples commerce and industry History Transmission Yellow fever disease New internaaonal recommendaaons Late
More informationSCIENTIFIC STUDY GROUP ON TRAVEL MEDICINE NATIONAL CONSENSUS MEETING 2018
SCIENTIFIC STUDY GROUP ON TRAVEL MEDICINE WETENSCHAPPELIJKE STUDIEGROEP REISGENEESKUNDE/GROUPE D'ETUDE SCIENTIFIQUE DE LA MEDECINE DES VOYAGES NATIONAL CONSENSUS MEETING 2018 Neder-over-Heembeek, October
More informationHow to Detect and Confirm Epidemic Yellow Fever
How to Detect and Confirm Epidemic Yellow Fever YF/Detect & Confirm/1 Purposes of Surveillance Detect epidemics early Estimate how many cases and deaths Assess extent of the epidemic See if an epidemic
More informationCHAPTER 8 Yellow fever
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Public Health Resources Public Health Resources 2015 CHAPTER 8 Yellow fever Mark D. Gershman Centers for Disease Control
More informationSuggested Exercises and Projects 395
Suggested Exercises and Projects 395 Projects These suggested projects are taken in part from the recent book A Course in Mathematical Biology: Quantitative Modeling with Mathematical and Computational
More informationHepatitis E in South Africa. Tongai Maponga
Hepatitis E in South Africa Tongai Maponga 7th FIDSSA CONGRESS 2017 This is what usually comes to mind History of hepatitis E virus An ET-NANB hepatitis virus later named HEV was first suspected in 1980.
More informationYellow fever Vaccine investment strategy
Yellow fever Vaccine investment strategy Background document #5 November 2013 Executive summary Since 2001, GAVI has spent ~$250M on yellow fever control $102M on routine vaccination in 17 countries ~$160M
More informationElizabeth Tenney Infectious Disease Epidemiology Homework 2 Texarkana Epidemic Measles in a Divided City Question 1a: Any outbreak of measles is cause
Elizabeth Tenney Infectious Disease Epidemiology Homework 2 Texarkana Epidemic Measles in a Divided City Question 1a: Any outbreak of measles is cause for concern, especially one with such a large increase
More informationVaccination Recommendations for Travellers from Polio-infected Countries: Report of the SAGE Polio Working Group
Vaccination Recommendations for Travellers from Polio-infected Countries: Report of the SAGE Polio Working Group Peter Figueroa, Chair SAGE Polio Working Group April 1, 2014 1 Overview Context for the
More informationin control group 7, , , ,
Q1 Rotavirus is a major cause of severe gastroenteritis among young children. Each year, rotavirus causes >500,000 deaths worldwide among infants and very young children, with 90% of these deaths occurring
More informationImmunization Update Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist
Immunization Update 2018 Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist Disclosures Merck speakers bureau Vaxserve speakers bureau Mrs. Jones shows up for her second ShingRix
More informationYellow fever vaccination in HIV patients
INFECTIOUS DISEASES DEPARTMENT AIDS REFERENCE CENTRE Yellow fever vaccination in HIV patients Dr Ch. MARTIN Travel & Vaccine Clinic CHU Saint-Pierre, Brussels Respect Innovation Engagement Solidarity Quality
More informationZika Virus Guidance for Medical Providers. Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department
Zika Virus Guidance for Medical Providers Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department Kern Perinatal Symposium March 3, 2017 CME DISCLOSURE The Planners,
More informationAppendix I (a) Human Surveillance Case Definition (Revised July 4, 2005)
Section A: Case Definitions Appendix I (a) Human Surveillance Case Definition (Revised July 4, 2005) The current Case Definitions were drafted with available information at the time of writing. Case Definitions
More informationNCCID RAPID REVIEW. 1. What are the case definitions and guidelines for surveillance and reporting purposes?
NCCID RAPID REVIEW 1. What are the case definitions and guidelines for surveillance and reporting purposes? Middle East Respiratory Syndrome Coronavirus: Ten Questions and Answers for Canadian Public Health
More informationTHE SITUATION OF YELLOW FEVER IN THE AFRICAN REGION: THE PLAN TO END YF EPIDEMICS IN 2026
THE SITUATION OF YELLOW FEVER IN THE AFRICAN REGION: THE PLAN TO END YF EPIDEMICS IN 2026 Dr Zabulon Yoti WHO AFRO Technical Coordinator for Health Emergencies 1 About 100 acute public health events annually
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationSeries of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)
UTAH PREVENTIVE CARE RECOMMENDATIONS Adult - Ages 19 and Above IMMUNIZATIONS CONTENTS: General Instructions Hepatitis A Hepatitis B Human Papilloma Virus Influenza Meningococcal A, C, Y, W (MCV4) Meningococcal
More informationEVIDENCE-TO-DECISION TABLE FOR FRACTIONAL DOSE YELLOW FEVER VACCINATION. Yellow fever vaccine: WHO position on the use of fractional doses, June 2017
EVIDENCE-TO-DECISION TABLE FOR FRACTIONAL DOSE YELLOW FEVER VACCINATION Yellow fever vaccine: WHO position on the use of fractional doses, June 2017 1 BENEFITS & HARMS OF THE OPTIONS PROBLEM Question:
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: West Nile Virus Illness Revised March 2017 West Nile Virus Illness
More informationWhat are the new active vaccine recommendations in the Canadian Immunization Guide?
154 CCDR 17 April 2014 Volume 40-8 https://doi.org/10.14745/ccdr.v40i08a03 1 What are the new active vaccine recommendations in the Canadian Immunization Guide? Warshawsky B 1 and Gemmill I 2 on behalf
More informationHepatitis B (HBV) vaccine: need for a booster injection? VHPB, Kyiv 2004
Hepatitis B (HBV) vaccine: need for a booster injection? VHPB, Kyiv 2004 Information for the Development of Immunization Policy 2002 update (WHO/V&B/02.28, printed: March 2003) The priorities for hepatitis
More informationRift Valley Fever RVF. Enhancing Safe Inter-Regional Livestock Trade Dubai, United Arab Emirates June 13-16, 2011
Rift Valley Fever RVF Enhancing Safe Inter-Regional Livestock Trade Dubai, United Arab Emirates June 13-16, 2011 Definition Rift valley fever (RVF) is an acute febrile arthropod-borne zoonotic disease.
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationFINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA
Comprehensive Family Immunization Family and Community Health Area FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES 24-26 AUGUST 2009, COSTA RICA Epidemiological
More informationSEA/CD/154 Distribution : General. Avian Influenza in South-East Asia Region: Priority Areas for Research
SEA/CD/154 Distribution : General Avian Influenza in South-East Asia Region: Priority Areas for Research World Health Organization Publications of the World Health Organization enjoy copyright protection
More informationRecommendations on pre-exposure rabies vaccine schedules
Recommendations on pre-exposure rabies vaccine schedules 25 Jan 2018 PATRICK SOENTJENS Chief Medical Physician Travel Clinic ITM, Antwerp Med LtCol Leading Physician ID4C/Travel Clinic Mil Hospital, Brussels
More informationProposed Recommendations. Terry Nolan
Proposed Recommendations CYD-TDV Denvaxia, Dengue Vaccine Terry Nolan SAGE, Co-Chair Dengue Vaccine WG WG Considerations A number of dimensions: Population benefit versus individual risk Ethical considerations
More informationWhat s Lurking out there??????
What s Lurking out there?????? Dave Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene david.warshauer@slh.wisc.edu WISCONSIN STATE LABORATORY OF HYGIENE
More informationMeasles and rubella monitoring January 2015
Measles and rubella monitoring January 215 Reporting on January December 214 surveillance data and epidemic intelligence data to the end of January 215 Main developments Measles During the 12-month period
More informationZika Virus. Robert Wittler, MD
Zika Virus Robert Wittler, MD Disclosure I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME
More informationZika Virus. Disclosure. Zika Virus 8/26/2016
Zika Virus Robert Wittler, MD Disclosure I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME
More informationTravel: Chikungunya, Zika,.. New worries
Travel: Chikungunya, Zika,.. New worries McGill Family Physician Refresher Course Dec 6, 2016 Makeda Semret, MD FRCP(C) Infectious Diseases/ Medical Microbiology Disclosures Funding from PHAC/CIHR/GSK/Novartis
More informationEpidemiologic and Clinical Features of Measles and Rubella in a Rural Area in China
ORIGINAL ARTICLE Epidemiologic and Clinical Features of Measles and Rubella in a Rural Area in China Youwang Yan* Health Bureau of Jingzhou District, Jingzhou City, Hubei Province, People s Republic of
More informationSeasonal Influenza. Provider Information Sheet. Infectious Disease Epidemiology Program
August 2007 te: This sheet contains information on seasonal influenza. For information on avian or pandemic influenza, contact the (800-423-1271 or 304-558-5358). What is influenza-like illness (ILI)?
More informationMeasles 2015: What We Need to Know
Faculty Measles 2015: What We Need to Know Karen Landers, MD, FAAP Assistant State Health Officer Tuberculosis Control and Immunization Alabama Department of Public Health Produced by the Alabama Department
More informationNo vaccine trade names are discussed. only)
Prospective evaluation of diphtheria-tetanus-acellular pertussis-polio-haemophilus influenzae type b (DTaP- IPV-Hib) and pneumococcal vaccination in children who completed chemotherapy for acute lymphocytic
More informationThe pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado.
Health Alert Network Tri-County Health Department Serving Adams, Arapahoe and Douglas Counties Phone 303/220-9200 Fax 303/741-4173 www.tchd.org Follow us on Twitter @TCHDHealth and @TCHDEmergency John
More informationImmunization for Child Hematopoietic Stem Cell Transplant (HSCT) Recipients
Immunization for Child Recipients January 4, 201 Immunization for Child Hematopoietic Stem Cell Transplant () Recipients Revision Date: January 4, 201 Note: This guide is meant to supplement existing recommendations
More informationHepatitis B at a Glance
Return completed form, preferably within 30 days of U.S. date of arrival, to address on reverse side of this form. Review overseas medical exam if available and document immunization dates. Indicate if
More informationIT S A LIFESAVER EVERY YEAR FLU CAUSES SEVERE ILLNESS AND DEATH. GET YOUR FLU VACCINE NOW. IF YOU ARE: worker
FLU VACCINE Information FOR Health care workers EVERY YEAR FLU CAUSES SEVERE ILLNESS AND DEATH. IF YOU ARE: A health care worker Over 65 Have a longterm illness Pregnant GET YOUR FLU VACCINE NOW. IT S
More informationSummary of current outbreak in Guinea, Liberia and Sierra Leone
ALERT TO HEALTHCARE WORKERS: EBOLA VIRUS DISEASE OUTBREAK IN GUINEA, LIBERIA AND SIERRA LEONE, WEST AFRICA 04 April 2014 Summary of current outbreak in Guinea, Liberia and Sierra Leone In this update and
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More informationIntroduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa
Introduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa Nigeria Center for Disease Control Federal Ministry of Health Abuja July 2015 Outline 1. Measles disease 2. Progress towards
More informationVaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications
Vaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications Vaccine Prematurity 1 Altered Immunocompetence 2 (excluding human immunodefi ciency virus [HIV] infection)
More informationMandates and More. Julie Morita, M.D. Deputy Commissioner Chicago Department of Public Health. Chicago Department of Public Health
Mandates and More Julie Morita, M.D. Deputy Chicago Department of Public Health Why are vaccines required for school entry? School Vaccine Requirements Small pox vaccine required in Massachusetts 1855
More informationA PERTUSSIS EPIDEMIC IN NSW: HOW EPIDEMIOLOGY REFLECTS VACCINATION POLICY
A PERTUSSIS EPIDEMIC IN NSW: HOW EPIDEMIOLOGY REFLECTS VACCINATION POLICY Julia Brotherton and Jeremy McAnulty Communicable Diseases Branch NSW Department of Health Pertussis has traditionally been considered
More informationWashoe County Health District Influenza Surveillance Program Final Hospitalization & Death Data
Washoe County Health District 2017-2018 Influenza Surveillance Program Final Hospitalization & Death Data Date: Monday, September 17, 2018 Overview of Hospitalized Cases, 2017-18 Influenza Surveillance
More informationThis is risky. Rabies. Are you at risk?
This is risky. Rabies Are you at risk? Are you at risk of rabies? You are at risk if you are in contact with potentially rabid animals: t Laboratory workers, veterinarians t Animal control workers, animal
More informationHIBA ABDALRAHIM Capsca Focal Point Public Health Authority
HIBA ABDALRAHIM Capsca Focal Point Public Health Authority Introduction Definition Symptom Transmission Global situation Local situation Control Content Introduction Yellow fever (YF) is a mosquito-borne
More informationUpdated Questions and Answers related to the dengue vaccine Dengvaxia and its use
WHO Secretariat Updated Questions and Answers related to the dengue vaccine Dengvaxia and its use Published 22 December 2017 This document takes into account new and unpublished data that were communicated
More informationCOFM Immunization Policy 2016
COFM Immunization Policy 2016 Council of Ontario Faculties of Medicine June 2016 COUNCIL OF ONTARIO FACULTIES OF MEDICINE An affiliate of the Council of Ontario Universities COFM Immunization Policy 2016
More informationEvidence to Recommendation Table 1
Evidence to Recommendation Table 1 Questions: Can the duration of the entire course and/or the number of doses administered of current PEP regimens be reduced while maintaining immunogenicity and effectiveness?
More informationInfluenza Backgrounder
Influenza Backgrounder Influenza Overview Influenza causes an average of 36,000 deaths and 200,000 hospitalizations in the U.S. every year. 1,2 Combined with pneumonia, influenza is the seventh leading
More informationIntroduction. Infections acquired by travellers
Introduction The number of Australians who travel overseas has increased steadily over recent years and now between 3.5 and 4.5 million exits are made annually. Although many of these trips are to countries
More informationGRADE-ing typhoid fever vaccination. Steve Schofield Force Health Protection Department of National Defence (DND) Canada
GRADE-ing typhoid fever vaccination Steve Schofield Force Health Protection Department of National Defence (DND) Canada Disclosure I have no conflict(s) of interest to declare Acknowledgements ( Team Typhoid
More informationYellow Fever: Background on Disease, Vaccine, and Recent Vaccine Developments
Yellow Fever: Background on Disease, Vaccine, and Recent Vaccine Developments J. Erin Staples, MD, PhD Arboviral Disease Branch, Centers for Disease Control and Prevention, Fort Collins, CO, USA Colorado
More informationMedia centre Ebola virus disease
1 of 6 10/15/2014 10:59 AM Media centre Ebola virus disease Fact sheet N 103 Updated September 2014 Key facts Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal
More informationMeningococcal Update. Disclosure. Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting
1 Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting 2 Disclosure Speakers Bureau: Sanofi Pasteur Vaccines and Novartis! I do not intend to discuss an unapproved/
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationGroups at risk for hepatitis B infection - who should be vaccinated
Groups at risk for hepatitis B infection - who should be vaccinated male homosexuals heterosexuals with multiple sex partners (e.g. sex workers) travelers to areas of high HBV endemicity immigrants and
More informationHEPATITIS B WHAT YOU NEED TO KNOW ARE YOU SURE YOU USE THE RIGHT MEASURES TO PROTECT YOURSELF AGAINST HEPATITIS B?
HEPATITIS B WHAT YOU NEED TO KNOW ARE YOU SURE YOU USE THE RIGHT MEASURES TO PROTECT YOURSELF AGAINST HEPATITIS B? GET INFORMED! GET VACCINATED! GET PROTECTED! HEPATITIS VACCINE DID YOU KNOW THAT? Hepatitis
More informationCase Classification West Nile Virus Neurological Syndrome (WNNS)
WEST NILE VIRUS Case definition Case Classification West Nile Virus Neurological Syndrome (WNNS) CONFIRMED CASE West Nile Virus Neurological Syndrome (WNNS) Clinical criteria AND at least one of the confirmed
More informationPolio vaccines and polio immunization in the pre-eradication era: WHO position paper. Published in WER 4 June, 2010
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper Published in WER 4 June, 2010 Epidemiology & Background Poliomyelitis (polio) is an acute communicable disease of humans
More informationSteps toward Measles Eradication in Japan A report from Okinawa Prefecture
Conferences and Lectures Steps toward Measles Eradication in Japan A report from Okinawa Prefecture JMAJ 53(1): 19 23, 2010 Kaoru ASHIMINE* 1 Okinawa, a Measles-endemic Prefecture in Japan In 1998 1999,
More informationEvents detected by national surveillance system (see Annex 1)
WHA58.3 ANNEX 2 DECISION INSTRUMENT FOR THE ASSESSMENT AND NOTIFICATION OF EVENTS THAT MAY CONSTITUTE A PUBLIC HEALTH EMERGENCY OF INTERNATIONAL CONCERN Events detected by national surveillance system
More informationCommittee: World Health Organization. Topic: The Zika Crisis. Chair: Ellen Flax. Director: Vikram Krishna. Contact:
Committee: World Health Organization Topic: The Zika Crisis Chair: Ellen Flax Director: Vikram Krishna Contact: Eflax17@sidwell.edu Dear Delegates, I am your chair, Ellen Flax, and I am so excited to see
More informationPERTUSSIS The Unpredictable Burden of Disease. Lawrence D. Frenkel, MD, FAAP AAP/Novartis Grand Rounds Webinar February 7, 2013
PERTUSSIS The Unpredictable Burden of Disease Lawrence D. Frenkel, MD, FAAP AAP/Novartis Grand Rounds Webinar February 7, 2013 Pertussis Agent Bordetella pertussis Nonmotile, fastidious, gram-negative,
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationConfronting Ebola. Keeping NY patients and healthcare workers safe and healthy
Confronting Ebola Keeping NY patients and healthcare workers safe and healthy All materials provided by Centers for Disease Control and Prevention. October 16, 2014 What You Need to Know about Ebola The
More information6. SURVEILLANCE AND OUTRBREAK RESPONSE
6. SURVEILLANCE AND OUTRBREAK RESPONSE The main objective of surveillance is to detect, in a timely manner, cases of CHIK in the Americas. Early detection will allow for proper response and characterization
More informationCOFM Immunization Policy
COUNCIL OF ONTARIO FACULTIES OF MEDICINE An affiliate of the Council of Ontario Universities COFM Immunization Policy This policy applies to all undergraduate medical students attending an Ontario medical
More informationImmunization for Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients
Immunization for Adult Recipients January 4, 201 Immunization for Adult Hematopoietic Stem Cell Transplant () Recipients Revision Date: January 4, 201 Note: This guide is meant to supplement existing recommendations
More information4.3.9 Pandemic Disease
4.3.9 Pandemic Disease This section describes the location and extent, range of magnitude, past occurrence, future occurrence, and vulnerability assessment for the pandemic disease hazard for Armstrong
More informationHepatitis B. Data from the Travel Health Surveillance Section of the Health Protection Agency Communicable Disease Surveillance Centre
Hepatitis B Introduction Hepatitis B virus is one of the most prevalent viruses worldwide and is a major cause of chronic liver disease and hepatocellular carcinoma. It is a hepadnavirus, consisting of
More informationZika Outbreak Discussion
Zika Outbreak Discussion May 10, 2016 2016 Zurich Healthcare Customer Symposium Speakers Krishna Lynch Senior Healthcare Risk Consultant Zurich Clayton Shoup Business Director, Workers Compensation Zurich
More informationNHS Greater Glasgow & Clyde SOP No. BMT Haemopoietic Stem Cell Transplantation Services Vaccination Policy
This policy was written with advice from Dr S Ahmed, Consultant in Public Health, Greater Glasgow & Clyde. We would like to thank him for his guidance. 1. Background It is recommended by EBMT and CDC that
More informationElizabeth Hinson ID Homework #2
Question 1: Would you call this an epidemic? I would consider this an epidemic, because an epidemic is the occurrence of cases of a condition in a population in a number greater than expected for a given
More informationGuide on Access to the Yellow Fever ICG Stockpile. Emergency Campaigns. International Coordinating Group on Vaccine. Geneva, Switzerland 2012
Guide on Access to the Yellow Fever ICG Stockpile Emergency Campaigns Geneva, Switzerland 2012 International Coordinating Group on Vaccine Provision for Yellow Fever Control TABLE OF CONTENTS 1. Description
More informationRecommended vaccines in the United States. Maki Kano, MD September 23, 2017 Apple Time
Recommended vaccines in the United States Maki Kano, MD September 23, 2017 Apple Time Recommended Vaccines 0 to 6 years old Recommended Vaccines 7 to 18 Vaccine schedule in Japan Vaccines in Japan Routine
More information